The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
Great Christmas present! Where is earache now???
The important point that needs not to be overlooked here is that it demonstrates ORPHs’ diversification as a CRO. Securing a repeat contract from an existing customer demonstrated also trust and satisfaction with performance. These factors are equally (if not more) relevant than the contract value at this time IMHO
I wouldn't allow yourselves to get too bent out of shape re SP fluctuations. I watched the Investor Meet Company the other day and I was very impressed by Stuart's objective and considered go to market strategy. Having had exposure to pharma and med device regulatory challenges in a past life, the company's initial focus on less regulated markets should make it easier to build scale and revenue needed to tackle the more onerous reg requirements of more heavily regulated industries. Just meeting pharma labelling and packaging regs is a huge obstacle to overcome. Needless to say, I'm now invested.
In any case, if you think you're having a red day on here, come and see what's going on for us invested in Open Orphan at the moment ;-)
I invested in ORPH with the hope of some good mid-term gains to build myself a nice new garage to house a couple of my classic cars and bikes . However with current performance, I'm looking at a 6 x 4 shed from Wickes in shiplap ;-). But, I'm keeping the faith because I believe the fundamentals of the business are strong and having previously worked in a tech start-up switching from products to services, the business took a hell of a lot longer to get established than anyone would have believed, hence patience is needed. As WB says, the stock market is a device invented to take money from the impatient and give it to the patient ;-).
Had a message from AJB this morning saying contrary to previous information, I won't see the shares in my account until the end of the lock-up period. See below:
Further to our previous communication, we have received an update regarding the Open Orphan Plc demerger event.
Please note that the Poolbeg shares will be in a lock-up period until 9 calendar months have passed from the date of admission to AIM. This means that you are not permitted to sell, transfer, or deal in the shares until the lock-up period is over.
The Poolbeg shares are expected to be admitted to AIM on 19 July 2021. If the shares are admitted on 19 July 2021, then you can expect the lock-up period to last until 19 April 2022. Croft Nominees Limited will hold the shares during the lock-up period and then distribute the share certificates upon the completion of the lock-up period.
Under the terms of the demerger, you will receive 1 new share in Poolbeg Pharma for every 2.98 Open Orphan shares held as of the record date, 17 June 2021.
Please be aware that you will not receive the shares in your account until the lock-up period has finished. We apologise for any confusion that our previous notification may have caused.
Great Stuff! Particularly like CF's explanation of what he means by 'significant' with ref to the AIM ImmunoTec. He said 'significant' means several million ;-)
Nothing showing in my AJB ISA as of yet, nor my wife's and daughter's ;-). I'm guessing they'll appear by close of play on the 19th latest.
We're almost due another 'Investor meets Company' briefing based on CF saying at the last one he'd like to do these on a monthly basis. We could then get an update on what's happening, even if the update is 'a delay'
The other thing to remember here is that whether CF was referring to a gov't or a commercial contract, the organisation's PR team will need to approve any announcement made by ORPH before it goes out. In my experience, this can take a couple of weeks and a lot of back and forth editing - it can be a real pain! The press release has to say more about what's in it for the customer rather than the supplier. Maintaining a competitive supplier base means customer PR teams also don't want to be seen as promoting any one supplier at the risk of upsetting others. Yes, if the deal has been done, ORPH could release the news as 'ANO Customer' , but why would they? Much better to wait until you can name the customer and do it all in one go, otherwise a subsequent press release risks promoting old news.
What some folks on here seem to be overlooking is that the deal CF promised may be done, but the customer (for whatever reason - and there could be many) has insisted on a news embargo. In my experience having worked for a number of start-ups in the past that are keen to post news of new contract wins with big customers, we sometimes had to agree to non-disclosure, sometimes for a few weeks, sometimes longer. Quite often this would be to allow the customer to brief other potential and existing suppliers that their existing relationships were not at risk. We mustn't forget that it's not all about ORPH (despite many of us wanting it to be). We need to take into account what ORPH's customers are mandating and if they say 'don't publish' then there's nothing ORPH can do other than be in breach of their contract.
Sit tight. I'm confident.
OK Si. Thanks for clarifying :-)
Does anyone know the current value of the Poolbeg shares? Am still waiting for mine to arrive in my AJB ISA.
Received this via AJ Bell earlier....
Description Preliminary Information Only
Notes Further to our previous communication, we have received an update regarding the Open Orphan Plc demerger event.
All resolutions were passed at the General Meeting held on 29 April 2021. The demerger still subject to approval at a Court Hearing on 18 May 2021, and if successful, is expected to become effective on or around 20 May 2021.
Please copy and paste the below FAQ link into your web browser for more information on corporate actions:
https://www.ajbell.co.uk/sites/ajbell.co.uk/files/AJB_Corporate_action_FAQs.pdf
IMPORTANT NOTE - If you have any questions or queries regarding this event, please send us a secure message and ensure you quote the following in the ?Subject? field: CORPORATE ACTION - Open Orphan Plc - 9642013
Updated: 06/05/21
***
Open Orphan Plc has announced a demerger, through which part of the company will be separated out and shareholders will receive shares in a newly-formed company (Newco).
Under the terms of the demerger, your account will be credited with 1 new share in Newco for each existing Open Orphan Plc share held.
The demerger is subject to shareholder approval at a general meeting to be held 29 April 2021.
If approved, you will not be able to sell, transfer or deal in Newco shares for up to nine months following admission of the Newco shares to trading on AIM. During this time, the shares will be in a lock-in period and transferred to Orph Parma IP Company Ltd.
To view the announcement in full, please copy and paste the following link into your web browser:
https://www.londonstockexchange.com/news-article/ORPH/potential-demerger-of-certain-non-core-assets/14934321
We strongly recommend you read the official document found within the above link. There may be dealing restrictions and/or increased charges when the resultant shares are in an overseas company. Where possible, we will make you aware of these charges.
Further information will be released upon receipt.
Please copy and paste the below FAQ link into your web browser for more information on corporate actions:
https://www.ajbell.co.uk/sites/ajbell.co.uk/files/AJB_Corporate_action_FAQs.pdf
IMPORTANT NOTE - If you have any questions or queries regarding this event, please send us a secure message and ensure you quote the following in the ?Subject? field: CORPORATE ACTION - Open Orphan Plc - 9643819
Updated: 19/04/21
earache is spot on here with the points he makes. My last job was working for a highly innovative SaaS start-up seeking to sell enterprise-wide labelling solutions into big pharma to make it easier for them to demonstrate FDA and EMA compliance whilst reducing the risk of product recalls and ultimately patient harm through labelling errors (it happens, believe me!).
One thing we learnt was that you can't rush big pharma and many of these organisations operate almost in a siloed fashion across research, development, manufacturing, requlatory, quality, supply chain, etc. We also learnt that whilst being highly inefficient through operating using archaic systems and processes across the approvals process, the folks using these processes knew how they worked and were very reluctant to accept change. As earache says, you have many folks holding influential regulatory positions who were working out their last years before retirement. Certainly in the US, many heads of regulatory were woman aged 50+ who you didn't want to upset because they had the power and authority to simply close the door on you. My point here being that you are never going to get any big pharma company to try to shortcut their regulatory processes and try to side-step the regulators. It simply isn't going to happen. You have to be tolerant and patient and be prepared to be in for a long sales cycle. But, once you're in, providing you don't mess up, you're in for a long time and there's lots of nice ongoing revenue streams and opportunities to expand.
I'm not sure if this post impacts anything that's already been said, other than we need to be patient. If folks on here want quick wins, they perhaps ought to be looking to invest elsewhere ;-)
OK. Happy Days then :-)
Hi All. I'm an existing ORPH shareholder and am considering increasing my investment. Can anyone tell me whether if I do that now, I'll still qualify for shares in the Newco if and when it's launched given the announcement this morning? Thanks in advance!